Table 2.
Time to CRPC and CSS According to Minimum, Medium, and Maximum First-Year Testosterone Levels During CAD (n = 626)
| Testosterone Level (nmol/L) | No. of Patients | Time to CRPC |
Time to Death Resulting From Prostate Cancer |
||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Median (years) | HR | 95% CI | P* | P† | Median (years) | HR | 95% CI | P* | P† | ||
| Minimum | .005 | .015 | .01 | .02 | |||||||
| < 0.7 | 489 | 10.00 | 1 | NR | 1 | ||||||
| 0.7 to 1.7 | 129 | 7.21 | 1.62 | 1.20 to 2.18 | 10.07 | 2.08 | 1.28 to 3.38 | ||||
| > 1.7 | 8 | 3.62 | 1.90 | 0.98 to 4.70 | NR | 2.93 | 0.70 to 12.30 | ||||
| Median | .01 | .02 | .27 | .27 | |||||||
| < 0.7 | 330 | NR | 1 | NR | 1 | ||||||
| 0.7 to 1.7 | 265 | 8.72 | 1.34 | 1.04 to 1.75 | NR | 1.29 | 0.83 to 2.00 | ||||
| > 1.7 | 31 | 6.00 | 1.97 | 1.18 to 3.26 | 6.00 | 1.86 | 0.82 to 4.21 | ||||
| Maximum | .03 | .03 | .01 | .02 | |||||||
| < 0.7 | 171 | NR | 1 | NR | 1 | ||||||
| 0.7 to 1.7 | 310 | 8.93 | 1.13 | 0.83 to 1.55 | 8.93 | 1.05 | 0.62 to 1.78 | ||||
| > 1.7 | 145 | 10.00 | 1.59 | 1.12 to 2.25 | 10.00 | 2.08 | 1.19 to 3.65 | ||||
Abbreviations: CAD, continuous androgen deprivation; CRPC, castration-resistant prostate cancer; CSS, cause-specific survival; HR, hazard ratio; NR, not reached.
*
Likelihood ratio test adjusted for age, time from completion of radiation therapy, Eastern Cooperative Oncology Group performance status, Gleason score, prior prostatectomy, and baseline testosterone level.
†
Adjusted for multiple tests based on Hochberg10 method.